Join
Live feed
·
PRReleasevia Quantisnow
Fulcrum Therapeutics Inc. logo

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

ByQuantisnow·Wall Street's wire, on your screen.
FULC· Fulcrum Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FULC (Fulcrum Therapeutics Inc.) and more on Quantisnow.